Texas Liver Institute

Recent papers from Texas Liver Institute

1. Elafibranor improves biochemical response and favorably modifies GLOBE and UK-PBC prognostic scores in primary biliary cholangitis: analyses from the phase III ELATIVE® trialBMC Gastroenterology · 2026
2. Treatment with elafibranor to normalize alkaline phosphatase in patients with primary biliary cholangitis and incomplete response to ursodeoxycholic acid: Results from the phase III randomized controlled ELSPIRE trialHepatology · 2026
3. Pharmacokinetics, Pharmacodynamics, and Safety of Plozasiran in Subjects With Renal or Hepatic ImpairmentAtherosclerosis · 2026
4. Pharmacokinetics and Safety of Obicetrapib in Moderate Hepatic Impairment: Phase I Study ResultsAtherosclerosis · 2026
5. Efficacy and safety of an 8-week bemnifosbuvir and ruzasvir regimen in chronic hepatitis C: Results from a Phase 2 studyHepatology · 2026
6. Pharmacokinetics and Pharmacodynamics of a Single Oral Dose of Ascelia‐Manganese‐Based MRI Contrast Agent (ACE‐MBCA) in Adult Subjects With and Without Hepatic ImpairmentJournal of Magnetic Resonance Imaging · 2026
7. A First-in-Human study of AHB-137, an unconjugated antisense oligonucleotide, in healthy subjects and patients with chronic hepatitis BHepatology · 2026
8. Weight reduction–dependent/–independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASHHepatology · 2026
9. Elafibranor in primary biliary cholangitis: two-year placebo-controlled outcomes and long-term open-label data from the ELATIVE® phase III trialJournal of Hepatology · 2026
10. Liver Biopsy in Metabolic Dysfunction‐Associated Steatohepatitis Clinical Trials: Potential Pitfalls and SolutionsLiver International · 2026
11. Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial˜The œLancet. Gastroenterology & hepatology · 2026
12. Development of a Patient Journey Map for Metabolic Dysfunction–Associated Steatohepatitis: A Comprehensive Assessment of the Patient Journey in North AmericaJournal of Patient Experience · 2026
13. Addressing Racial Disparities in a Hispanic Population Through Living Donor Liver Transplantation—A Comparison of 2 ErasClinical Transplantation · 2026
14. Efficacy and safety of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis: The randomized, placebo-controlled NAVIGATE trial.2026
15. A Multi-Analyte cfDNA-based Blood Test for Early Detection of Hepatocellular CarcinomaJournal of Hepatology · 2026
16. Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studiesHepatology Communications · 2026
17. Baseline Alkaline Phosphatase Impacts Response Rates in Primary Biliary Cholangitis: Exploring Response to Elafibranor in ELATIVELiver International · 2026
18. A randomized, open-label, Phase 2a study to assess the safety, pharmacodynamics, and pharmacokinetics of YAQ007 versus rifaximin in cirrhosisHepatology · 2026
19. Metabolic profiles and hepatic steatosis assessed by controlled attenuation parameter and elastography during Ramadan fasting in San Antonio, United StatesWorld Journal of Radiology · 2026
20. Pharmacokinetics and Safety of a Single Dose of Brensocatib in Participants with Hepatic Impairment and Matched Participants with Normal Hepatic FunctionsClinical Pharmacokinetics · 2026